UTHR logo

United Therapeutics (UTHR) Cash From Operations

Annual CFO

$978.00 M
+$175.50 M+21.87%

December 31, 2023

Summary

Performance

1-Year Change

+21.87%

3-Year Change

+29.42%

5-Year Change

+25.64%

15-Year Change

+106.24%

UTHR Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

95.28%
UTHR annual cash flow from operations is higher than 95.28% of companies in Healthcare sector

High & Low

All-time High

$978.00 M
UTHR annual cash flow from operations is currently at an all-time high

3-Year Low

$598.20 M
UTHR annual cash flow from operations is currently +63.49% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
UTHR previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 21, 2025
UTHR next annual earnings announcement is scheduled for Feb 21, 2025

OtherUTHRcash flowmetrics:

Annual CFI

-$719.60 M
UTHR annual cash flow from investing activities is -$719.60 million

Annual CFF

-$11.90 M
UTHR annual cash flow from financing activities is -$11.90 million

Annual FCF

$747.60 M
UTHR annual free cash flow is $747.60 million

Annual CAPEX

$230.40 M
UTHR annual capital expenditures is $230.40 million

Quarterly CFO

$377.20 M
+$145.00 M+62.45%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+8.95%

3-Year Change

+8.95%

5-Year Change

+75.77%

UTHR Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

96.5%
UTHR quarterly cash flow from operations is higher than 96.5% of companies in Healthcare sector

High & Low

All-time High

$377.20 M
UTHR quarterly cash flow from operations is currently at an all-time high

3-Year Low

$106.30 M
UTHR quarterly cash flow from operations is currently +254.84% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
UTHR previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 21, 2025
UTHR next earnings announcement is scheduled for Feb 21, 2025

OtherUTHRcash flowmetrics:

Quarterly CFI

-$114.90 M
UTHR quarterly cash flow from investing activities is -$114.90 million

Quarterly CFF

-$64.10 M
UTHR quarterly cash flow from financing activities is -$64.10 million

Quarterly FCF

$300.70 M
UTHR quarterly free cash flow is $300.70 million

Quarterly CAPEX

$76.50 M
UTHR quarterly capital expenditures is $76.50 million

TTM CFO

$1.14 B
+$31.00 M+2.80%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+18.95%

3-Year Change

+18.95%

5-Year Change

+78.88%

UTHR TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

96.07%
UTHR TTM cash flow from operations is higher than 96.07% of companies in Healthcare sector

High & Low

All-time High

$1.14 B
UTHR TTM cash flow from operations is currently at an all-time high

3-Year Low

$598.20 M
UTHR TTM cash flow from operations is currently +90.00% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
UTHR previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 21, 2025
UTHR next earnings announcement is scheduled for Feb 21, 2025

OtherUTHRcash flowmetrics:

TTM CFI

$582.50 M
UTHR TTM cash flow from investing activities is $582.50 million

TTM CFF

-$1.27 B
UTHR TTM cash flow from financing activities is -$1.27 billion

TTM FCF

$898.10 M
UTHR TTM free cash flow is $898.10 million

TTM CAPEX

$238.50 M
UTHR TTM capital expenditures is $238.50 million

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

UTHR Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+21.9%+8.9%+18.9%
3 y3 years+29.4%+8.9%+18.9%
5 y5 years+25.6%+75.8%+78.9%

UTHR Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+63.5%at high+254.8%at high+90.0%
5 y5-yearat high+573.4%at high+320.0%at high+650.1%
alltimeall timeat high+573.4%at high+160.1%at high+608.1%

United Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
$377.20 M(+62.4%)
$1.14 B(+2.8%)
Jun 2024
-
$232.20 M(-38.3%)
$1.11 B(+12.9%)
Mar 2024
-
$376.50 M(+149.8%)
$979.70 M(+0.2%)
Dec 2023
$978.00 M(+21.9%)
$150.70 M(-56.5%)
$978.00 M(+2.4%)
Sep 2023
-
$346.20 M(+225.7%)
$955.50 M(+10.1%)
Jun 2023
-
$106.30 M(-71.6%)
$867.90 M(-2.3%)
Mar 2023
-
$374.80 M(+192.4%)
$888.60 M(+10.7%)
Dec 2022
$802.50 M(+34.2%)
$128.20 M(-50.4%)
$802.50 M(-5.5%)
Sep 2022
-
$258.60 M(+103.6%)
$848.90 M(+9.4%)
Jun 2022
-
$127.00 M(-56.0%)
$775.90 M(-2.7%)
Mar 2022
-
$288.70 M(+65.3%)
$797.10 M(+33.2%)
Dec 2021
$598.20 M(-20.8%)
$174.60 M(-5.9%)
$598.20 M(+8.8%)
Sep 2021
-
$185.60 M(+25.2%)
$549.80 M(-10.6%)
Jun 2021
-
$148.20 M(+65.0%)
$615.10 M(-2.5%)
Mar 2021
-
$89.80 M(-28.8%)
$630.90 M(-16.5%)
Dec 2020
$755.70 M(-465.8%)
$126.20 M(-49.7%)
$755.70 M(+3.2%)
Sep 2020
-
$250.90 M(+53.0%)
$732.00 M(+9.8%)
Jun 2020
-
$164.00 M(-23.6%)
$666.50 M(+4.9%)
Mar 2020
-
$214.60 M(+109.4%)
$635.40 M(-407.6%)
Dec 2019
-$206.60 M(-126.5%)
$102.50 M(-44.7%)
-$206.60 M(-7.6%)
Sep 2019
-
$185.40 M(+39.5%)
-$223.70 M(+30.4%)
Jun 2019
-
$132.90 M(-121.2%)
-$171.60 M(+37.6%)
Mar 2019
-
-$627.40 M(-834.7%)
-$124.70 M(-116.0%)
Dec 2018
$778.40 M(+64.2%)
$85.40 M(-64.0%)
$778.40 M(+28.2%)
Sep 2018
-
$237.50 M(+32.1%)
$607.20 M(-3.3%)
Jun 2018
-
$179.80 M(-34.8%)
$628.20 M(+21.0%)
Mar 2018
-
$275.70 M(-421.3%)
$519.10 M(+9.5%)
Dec 2017
$474.20 M(-26.3%)
-$85.80 M(-133.2%)
$474.20 M(-34.4%)
Sep 2017
-
$258.50 M(+265.6%)
$723.40 M(+4.3%)
Jun 2017
-
$70.70 M(-69.4%)
$693.60 M(-7.3%)
Mar 2017
-
$230.80 M(+41.2%)
$748.60 M(+16.3%)
Dec 2016
$643.60 M(+68.1%)
$163.40 M(-28.6%)
$643.60 M(+27.3%)
Sep 2016
-
$228.70 M(+81.9%)
$505.70 M(+4.4%)
Jun 2016
-
$125.70 M(-0.1%)
$484.20 M(+21.2%)
Mar 2016
-
$125.80 M(+393.3%)
$399.50 M(+4.4%)
Dec 2015
$382.80 M(+7.7%)
$25.50 M(-87.7%)
$382.80 M(-14.5%)
Sep 2015
-
$207.20 M(+405.4%)
$447.95 M(-0.3%)
Jun 2015
-
$41.00 M(-62.4%)
$449.28 M(+27.0%)
Mar 2015
-
$109.10 M(+20.4%)
$353.80 M(-0.4%)
Dec 2014
$355.30 M(-16.5%)
$90.65 M(-56.5%)
$355.30 M(-3.7%)
Sep 2014
-
$208.54 M(-482.8%)
$369.07 M(+23.1%)
Jun 2014
-
-$54.48 M(-149.3%)
$299.84 M(-31.6%)
Mar 2014
-
$110.60 M(+5.9%)
$438.17 M(+3.0%)
Dec 2013
$425.27 M(+31.4%)
$104.42 M(-25.0%)
$425.27 M(-0.2%)
Sep 2013
-
$139.30 M(+66.1%)
$426.06 M(+12.1%)
Jun 2013
-
$83.85 M(-14.2%)
$380.20 M(-0.9%)
Mar 2013
-
$97.70 M(-7.1%)
$383.74 M(+18.6%)
Dec 2012
$323.63 M(+29.4%)
$105.21 M(+12.6%)
$323.63 M(+19.8%)
Sep 2012
-
$93.45 M(+6.9%)
$270.05 M(+5.0%)
Jun 2012
-
$87.39 M(+132.5%)
$257.28 M(+9.7%)
Mar 2012
-
$37.59 M(-27.2%)
$234.43 M(-6.3%)
Dec 2011
$250.19 M
$51.63 M(-36.0%)
$250.19 M(+5.2%)
DateAnnualQuarterlyTTM
Sep 2011
-
$80.68 M(+25.0%)
$237.82 M(-8.5%)
Jun 2011
-
$64.54 M(+21.0%)
$259.97 M(+12.7%)
Mar 2011
-
$53.35 M(+35.9%)
$230.66 M(+9.0%)
Dec 2010
$211.53 M(+112.1%)
$39.25 M(-61.8%)
$211.53 M(+6.5%)
Sep 2010
-
$102.83 M(+191.9%)
$198.60 M(+77.7%)
Jun 2010
-
$35.23 M(+3.0%)
$111.76 M(-14.0%)
Mar 2010
-
$34.22 M(+30.0%)
$129.91 M(+30.3%)
Dec 2009
$99.72 M(-302.7%)
$26.32 M(+64.6%)
$99.72 M(-286.3%)
Sep 2009
-
$15.99 M(-70.0%)
-$53.54 M(-8.0%)
Jun 2009
-
$53.38 M(+1222.2%)
-$58.19 M(-27.4%)
Mar 2009
-
$4.04 M(-103.2%)
-$80.19 M(+63.0%)
Dec 2008
-$49.20 M(-200.5%)
-$126.94 M(-1219.6%)
-$49.20 M(-174.5%)
Sep 2008
-
$11.34 M(-63.9%)
$66.05 M(-19.5%)
Jun 2008
-
$31.38 M(-10.4%)
$82.01 M(+17.0%)
Mar 2008
-
$35.03 M(-399.5%)
$70.07 M(+43.2%)
Dec 2007
$48.95 M(-0.9%)
-$11.70 M(-142.8%)
$48.95 M(-9.6%)
Sep 2007
-
$27.31 M(+40.5%)
$54.13 M(+19.3%)
Jun 2007
-
$19.43 M(+39.8%)
$45.37 M(-3.1%)
Mar 2007
-
$13.90 M(-313.5%)
$46.81 M(-5.2%)
Dec 2006
$49.39 M(+14.4%)
-$6.51 M(-135.1%)
$49.39 M(-22.2%)
Sep 2006
-
$18.54 M(-11.2%)
$63.47 M(+5.6%)
Jun 2006
-
$20.88 M(+26.7%)
$60.12 M(+10.3%)
Mar 2006
-
$16.48 M(+117.6%)
$54.50 M(+26.3%)
Dec 2005
$43.17 M(+107.7%)
$7.57 M(-50.1%)
$43.17 M(+11.0%)
Sep 2005
-
$15.19 M(-0.5%)
$38.89 M(+16.6%)
Jun 2005
-
$15.26 M(+196.2%)
$33.36 M(+30.4%)
Mar 2005
-
$5.15 M(+56.2%)
$25.59 M(+23.2%)
Dec 2004
$20.78 M(-342.7%)
$3.30 M(-65.9%)
$20.78 M(+229.2%)
Sep 2004
-
$9.66 M(+29.0%)
$6.31 M(+515.7%)
Jun 2004
-
$7.49 M(+2114.8%)
$1.02 M(-113.2%)
Mar 2004
-
$338.00 K(-103.0%)
-$7.79 M(-9.0%)
Dec 2003
-$8.56 M(-61.5%)
-$11.17 M(-355.5%)
-$8.56 M(-397.5%)
Sep 2003
-
$4.37 M(-427.9%)
$2.88 M(-135.1%)
Jun 2003
-
-$1.33 M(+210.0%)
-$8.19 M(-42.2%)
Mar 2003
-
-$430.00 K(-259.3%)
-$14.17 M(-36.3%)
Dec 2002
-$22.26 M(-42.8%)
$270.00 K(-104.0%)
-$22.26 M(-25.6%)
Sep 2002
-
-$6.70 M(-8.4%)
-$29.91 M(-15.0%)
Jun 2002
-
-$7.31 M(-14.2%)
-$35.18 M(-9.4%)
Mar 2002
-
-$8.52 M(+15.5%)
-$38.82 M(-0.2%)
Dec 2001
-$38.90 M(+25.0%)
-$7.38 M(-38.4%)
-$38.90 M(-6.4%)
Sep 2001
-
-$11.97 M(+9.3%)
-$41.54 M(+19.8%)
Jun 2001
-
-$10.96 M(+27.5%)
-$34.67 M(+6.3%)
Mar 2001
-
-$8.59 M(-14.2%)
-$32.61 M(+4.8%)
Dec 2000
-$31.11 M(+31.3%)
-$10.02 M(+96.6%)
-$31.11 M(+8.1%)
Sep 2000
-
-$5.10 M(-42.7%)
-$28.79 M(-1.4%)
Jun 2000
-
-$8.89 M(+25.2%)
-$29.20 M(+5.0%)
Mar 2000
-
-$7.10 M(-7.7%)
-$27.80 M(+17.3%)
Dec 1999
-$23.70 M(+146.9%)
-$7.70 M(+40.0%)
-$23.70 M(+48.1%)
Sep 1999
-
-$5.50 M(-26.7%)
-$16.00 M(+52.4%)
Jun 1999
-
-$7.50 M(+150.0%)
-$10.50 M(+250.0%)
Mar 1999
-
-$3.00 M
-$3.00 M
Dec 1998
-$9.60 M
-
-

FAQ

  • What is United Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for United Therapeutics?
  • What is United Therapeutics annual CFO year-on-year change?
  • What is United Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for United Therapeutics?
  • What is United Therapeutics quarterly CFO year-on-year change?
  • What is United Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for United Therapeutics?
  • What is United Therapeutics TTM CFO year-on-year change?

What is United Therapeutics annual cash flow from operations?

The current annual CFO of UTHR is $978.00 M

What is the all time high annual CFO for United Therapeutics?

United Therapeutics all-time high annual cash flow from operations is $978.00 M

What is United Therapeutics annual CFO year-on-year change?

Over the past year, UTHR annual cash flow from operations has changed by +$175.50 M (+21.87%)

What is United Therapeutics quarterly cash flow from operations?

The current quarterly CFO of UTHR is $377.20 M

What is the all time high quarterly CFO for United Therapeutics?

United Therapeutics all-time high quarterly cash flow from operations is $377.20 M

What is United Therapeutics quarterly CFO year-on-year change?

Over the past year, UTHR quarterly cash flow from operations has changed by +$31.00 M (+8.95%)

What is United Therapeutics TTM cash flow from operations?

The current TTM CFO of UTHR is $1.14 B

What is the all time high TTM CFO for United Therapeutics?

United Therapeutics all-time high TTM cash flow from operations is $1.14 B

What is United Therapeutics TTM CFO year-on-year change?

Over the past year, UTHR TTM cash flow from operations has changed by +$181.10 M (+18.95%)